The University of Chicago Header Logo

Connection

Rima McLeod to Toxoplasma

Back to Details
This is a "connection" page, showing publications Rima McLeod has written about Toxoplasma.
Rima McLeod
Connection Strength
10.839
Toxoplasma
  1. Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Front Cell Infect Microbiol. 2020; 10:203.
    View in: PubMed
    Score: 0.608
  2. Seroprevalence of Toxoplasma gondii in domestic pets from metropolitan regions of Panama. Parasite. 2017; 24:9.
    View in: PubMed
    Score: 0.486
  3. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016 07 14; 6:29179.
    View in: PubMed
    Score: 0.464
  4. Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics. Clin Infect Dis. 2015 Dec 15; 61(12):1831-4.
    View in: PubMed
    Score: 0.439
  5. Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2014; 58(3):1789-92.
    View in: PubMed
    Score: 0.389
  6. Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase. Bioorg Med Chem Lett. 2013 Apr 01; 23(7):2035-43.
    View in: PubMed
    Score: 0.366
  7. Salicylanilide inhibitors of Toxoplasma gondii. J Med Chem. 2012 Oct 11; 55(19):8375-91.
    View in: PubMed
    Score: 0.357
  8. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14182-7.
    View in: PubMed
    Score: 0.354
  9. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012 Jun; 54(11):1595-605.
    View in: PubMed
    Score: 0.346
  10. Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother. 2012 May; 56(5):2666-82.
    View in: PubMed
    Score: 0.342
  11. Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. Parasitology. 2012 Jan; 139(1):1-13.
    View in: PubMed
    Score: 0.336
  12. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-? and reduces parasite burden in HLA-B*0702 mice. Hum Immunol. 2012 Jan; 73(1):1-10.
    View in: PubMed
    Score: 0.334
  13. T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One. 2010 Nov 22; 5(11):e14057.
    View in: PubMed
    Score: 0.314
  14. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine. 2011 Jan 17; 29(4):754-62.
    View in: PubMed
    Score: 0.314
  15. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem. 2010 Sep 09; 53(17):6287-300.
    View in: PubMed
    Score: 0.310
  16. Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis. 2008 Mar 05; 2(3):e190.
    View in: PubMed
    Score: 0.260
  17. Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2005 Aug; 49(8):3463-7.
    View in: PubMed
    Score: 0.217
  18. Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more. PLoS Negl Trop Dis. 2024 May; 18(5):e0011335.
    View in: PubMed
    Score: 0.200
  19. Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A. 2003 Nov 25; 100(24):14281-6.
    View in: PubMed
    Score: 0.193
  20. Performances of ICT Toxoplasma IgG-IgM test in comparison with Vidas® toxo competition to determine the immune status against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 2023 Nov; 42(11):1327-1335.
    View in: PubMed
    Score: 0.191
  21. Evaluation of the acceptability of point of care diagnostic test for prenatal toxoplasmosis (translational research phase III). J Infect Public Health. 2023 Jan; 16(1):15-24.
    View in: PubMed
    Score: 0.180
  22. In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol. 2002 Jul 15; 169(2):966-73.
    View in: PubMed
    Score: 0.176
  23. Genetic analysis of influences on survival following Toxoplasma gondii infection. Int J Parasitol. 2002 Feb; 32(2):179-85.
    View in: PubMed
    Score: 0.170
  24. High performance of a novel point-of-care blood test for Toxoplasma infection in women from diverse regions of Morocco. Emerg Microbes Infect. 2021 Dec; 10(1):1675-1682.
    View in: PubMed
    Score: 0.168
  25. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol. 2001 Feb; 31(2):109-13.
    View in: PubMed
    Score: 0.159
  26. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Sci Rep. 2020 10 12; 10(1):16984.
    View in: PubMed
    Score: 0.156
  27. Measurement of the efficacy of vaccines and antimicrobial therapy against infection with Toxoplasma gondii. Int J Parasitol. 2000 Feb; 30(2):149-55.
    View in: PubMed
    Score: 0.148
  28. CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii. Front Cell Infect Microbiol. 2018; 8:352.
    View in: PubMed
    Score: 0.135
  29. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerg Microbes Infect. 2018 Sep 27; 7(1):165.
    View in: PubMed
    Score: 0.135
  30. Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 2017 Jun; 11(6):e0005670.
    View in: PubMed
    Score: 0.124
  31. Prevalence and genetic characterization of Toxoplasma gondii in free-range chickens from grocery stores and farms in Maryland, Ohio and Massachusetts, USA. Parasitol Res. 2017 May; 116(5):1591-1595.
    View in: PubMed
    Score: 0.122
  32. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. 1996 Nov; 23(5):1055-60.
    View in: PubMed
    Score: 0.118
  33. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight. 2016 09 22; 1(15):e85955.
    View in: PubMed
    Score: 0.118
  34. Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Elife. 2016 Jan 29; 5.
    View in: PubMed
    Score: 0.112
  35. Effects of human class I transgenes on Toxoplasma gondii cyst formation. J Immunol. 1994 May 01; 152(9):4537-41.
    View in: PubMed
    Score: 0.100
  36. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014 May 30; 32(26):3243-8.
    View in: PubMed
    Score: 0.099
  37. The benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme target. Bioorg Med Chem Lett. 2014 Feb 01; 24(3):911-6.
    View in: PubMed
    Score: 0.097
  38. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry. 2013 Dec 23; 52(51):9155-66.
    View in: PubMed
    Score: 0.097
  39. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem. 2013 Jul; 8(7):1138-60.
    View in: PubMed
    Score: 0.094
  40. Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg Med Chem Lett. 2013 Jun 15; 23(12):3551-5.
    View in: PubMed
    Score: 0.093
  41. Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii. Infect Immun. 2012 Dec; 80(12):4298-308.
    View in: PubMed
    Score: 0.089
  42. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J. 2011 Dec; 30(12):1056-61.
    View in: PubMed
    Score: 0.084
  43. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis. 2011 Dec; 53(11):1081-9.
    View in: PubMed
    Score: 0.084
  44. Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol. 2011 Apr; 97(2):328-37.
    View in: PubMed
    Score: 0.080
  45. Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des. 2011 May; 25(5):403-11.
    View in: PubMed
    Score: 0.080
  46. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun. 2011 Feb; 79(2):756-66.
    View in: PubMed
    Score: 0.078
  47. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol. 2010 Nov; 26(11):550-5.
    View in: PubMed
    Score: 0.076
  48. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine. 2010 May 21; 28(23):3977-89.
    View in: PubMed
    Score: 0.075
  49. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009 Mar; 104(2):320-44.
    View in: PubMed
    Score: 0.070
  50. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation. 2008 Oct 23; 5:48.
    View in: PubMed
    Score: 0.068
  51. Subcellular localization and dynamics of a digalactolipid-like epitope in Toxoplasma gondii. J Lipid Res. 2008 Apr; 49(4):746-62.
    View in: PubMed
    Score: 0.064
  52. Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry. 2007 Dec 04; 46(48):13882-90.
    View in: PubMed
    Score: 0.064
  53. Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr. 2007 Mar; 63(Pt 3):328-38.
    View in: PubMed
    Score: 0.061
  54. Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Jun 01; 62(Pt 6):604-6.
    View in: PubMed
    Score: 0.058
  55. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis J. 2006 Mar; 25(3):270-2.
    View in: PubMed
    Score: 0.057
  56. Impact of education on knowledge, attitudes, and practices for gestational toxoplasmosis. J Infect Public Health. 2024 Sep; 17(9):102516.
    View in: PubMed
    Score: 0.051
  57. Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol. 2004 Mar 09; 34(3):297-308.
    View in: PubMed
    Score: 0.049
  58. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol. 2002 May; 18(5):198-201.
    View in: PubMed
    Score: 0.043
  59. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci U S A. 1999 Nov 09; 96(23):13387-92.
    View in: PubMed
    Score: 0.037
  60. The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies. Ecohealth. 2019 06; 16(2):378-390.
    View in: PubMed
    Score: 0.035
  61. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for anti-Toxoplasma antibodies. PLoS Negl Trop Dis. 2018 08; 12(8):e0006536.
    View in: PubMed
    Score: 0.034
  62. The zebrafish, Danio rerio, as a model for Toxoplasma gondii: an initial description of infection in fish. J Fish Dis. 2015 Jul; 38(7):675-9.
    View in: PubMed
    Score: 0.027
  63. Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J Immunol. 1990 Nov 15; 145(10):3438-41.
    View in: PubMed
    Score: 0.020
  64. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol. 2010 Jun 15; 184(12):7040-6.
    View in: PubMed
    Score: 0.019
  65. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008 Sep; 146(3):375-384.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.